Emerging Treatment Options for the Management of Metastatic Colorectal Cancer

Presenter: Dustin A. Deming
Restricted access

An improved understanding of the molecular landscape of metastatic colorectal cancer (CRC) has opened the door for new treatment options. Clinicians should test for molecular alterations that predict resistance to epidermal growth factor receptor (EGFR) inhibitors, such as KRAS and NRAS, and additionally clinically actionable alterations, including BRAF V600 mutations, HER2 amplification, NTRK fusions, and mismatch repair deficiency. Improved outcomes can be achieved with precision treatment strategies for the various CRC subtypes, although clinical features, such as tumor bulk and patient performance status, still help to guide treatment choice. Immune therapies have also produced impressive results in patients with mismatch repair–deficient/microsatellite instability–high tumors. These newer approaches were recently incorporated into the NCCN Guidelines for Colon and Rectal Cancers. In the future, these newer approaches may be used in earlier treatment settings.

Disclosures: Dr. Deming has disclosed that he receives grant/research support from AbbVie, Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Serono, Merck & Co., Inc., and Revolution Machines; is a scientific advisor for Bayer HealthCare, Bristol-Myers Squibb Company, Genentech, Inc., Ipsen, Novocure, Array BioPharma, Promega, and Taiho Parmaceuticals Co., Ltd.; and receives consulting fees from Bayer HealthCare, Bristol-Myers Squibb Company, Genentech, Inc., Ipsen, Novocure, Array BioPharma, Promega, Taiho Parmaceuticals Co., Ltd.

Correspondence: Dustin A. Deming, MD, University of Wisconsin Carbone Cancer Center, 1111 Highland Avenue, WIMR11 6507, Madison, WI 53702. Email: ddeming@medicine.wisc.edu
  • 1.

    Koopman M, Kortman GA, Mekenkamp L, Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266273.

  • 2.

    Le DT, Kim TW, Van Cutsem E, Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 2020;38:1119.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Overman MJ, Lonardi S, Wong KYM, Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36:773779.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Lenz HJ, Lonardi S, Zagonel V, Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair-deficient metastatic colorectal cancer: clinical update [abstract]. Presented at the ASCO 2020 Gastrointestinal Cancers Symposium; January 23–25, 2020; San Francisco, California. Abstract 11.

    • Crossref
    • Export Citation
  • 5.

    Andre T, Shiu KK, Kim TW, Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 study [abstract]. Presented at the ASCO20 Virtual Scientific Program; May 29–31, 2020; Chicago, Illlinois. Abstract LBA4.

  • 6.

    Benson AB III, Venook AP, Al-Hawary MM, NCCN Clinical Practice Guidelines in Oncology for Colon Cancer. Version 2.2020. Accessed March 1, 2020. Available at NCCN.org

    • Search Google Scholar
    • Export Citation
  • 7.

    Cremolini C, Loupakis F, Antoniotti C, FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16:13061315.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Cremolini C, Antoniotti C, Lonardi S, Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first- and second-line treatment of unresectable mCRC [abstract]. J Clin Oncol 2019;37(Suppl 15):Abstract 3508.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Kopetz S, Grothey A, Yaeger R, Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019;381:16321643.

  • 10.

    Kopetz S, Grothey A, Van Cutsem E, Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: quality-of-life results from a randomized, three-arm, phase III study versus the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC) [abstract]. J Clin Oncol 2020;38(Suppl 1):Abstract 8.

    • Search Google Scholar
    • Export Citation
  • 11.

    Meric-Bernstam F, Hurwitz H, Raghav KPS, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019;20:518530.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Sartore-Bianchi A, Trusolino L, Martino C, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738746.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Venook AP, Niedzwiecki D, Innocenti F, Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance) [abstract]. J Clin Oncol 2017;34(Suppl):Abstract 3504.

    • Search Google Scholar
    • Export Citation
  • 14.

    Tejpar S, Stintzing S, Ciardiello F, Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2017;3:194201.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Kratz JD, Uboha NV, Lubner SJ, Metastatic bulk independently predicts outcomes for EGFR precision targeting in colorectal cancer. J Natl Compr Canc Netw 2018;16:14421450.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Mauri G, Pizzutilo EG, Amatu A, Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: systematic review of different strategies. Cancer Treat Rev 2019;73:4153.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Liu X, George GC, Tsimberidou AM, Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer 2015;15:713.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Doebele RC, Drilon A, Paz-Ares L, Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271282.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Hong DS, DuBois SG, Kummar S, Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21:531540.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 546 546 546
PDF Downloads 180 180 180
EPUB Downloads 0 0 0